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Genetically Modified Organisms
in Food: Ethical Tensions and
the Labeling Initiative
Debra M. Strauss*
Charles F. Dolan School of Business, Fairfield University, Fairfield,
Connecticut, USA

Introduction
This chapter explores the ethical implications of genetically modified organisms
(GMOs) in food that originate from plants
genetically altered through bioengineering.
The tensions between the proliferation of
agricultural biotechnology and consumer
concerns about potential harm to human
health and the environment ultimately cause
us to reflect on the current regulatory scheme
in the USA. Does the failure to require adequate, meaningful labeling, and the preemption of grassroots efforts to do so, violate
our right to informed consent by not allowing consumers a choice as to whether to
knowingly and willingly assume the risks of
ingesting GMOs?
Genetically modified (GM) plants involve
a uniquely invasive application of agricultural biotechnology, unlike traditional plant
breeding and hybrid methods used in the
past. Through this novel process, the DNA of
one organism is inserted into another, causing the target trait to be expressed in that
non-related species at the cellular level
throughout the plant, including the fruit or
vegetable and the component ingredients
that become part of a variety of food products. Most commonly, GM plants are engineered to withstand a weed-killing pesticide,
Roundup, sold by Monsanto along with the
herbicide-resistant varieties of soybeans,

canola, cotton, corn, radicchio, rice and sugar beet. In addition, genes derived from a
bacterium in the soil used as an insecticide,
Bacillus thuringiensis (Bt), have been inserted into crops to induce the plant to produce
a toxin against certain insects, producing Btcorn, Bt-cotton, Bt-potatoes, Bt-rice and
Bt-tomatoes (Strauss, 2006).
There is even a biotechnology invention,
as yet undeveloped for commercial use due
to widespread consumer opposition in the
international community, called the ‘Terminator’ gene, also known as Genetic Use
Restriction Technologies (GURTs). Developed
jointly by the agricultural biotechnology
industry and the United States Department
of Agriculture (USDA), this technology genetically alters plants to produce sterile
seeds at harvest, effectively blocking the
ability of the plant to procreate future generations in order to prevent farmers’ traditional
practice of saving and replanting harvested
seed and thereby necessitating the purchase
of new seeds from the biotechnology company each year (Strauss, 2009). Recognizing the conceivable catastrophic effect on
the global food supply if spread via common cross-pollination, the United Nations,
through the UN Convention on Biological
Diversity in 2000, implemented and has
continued to maintain a de facto moratorium
on these sterile seed technologies (Convention
on Biological Diversity, 2017). Ultimately,

* E-mail: DStrauss@fairfield.edu
© CAB International 2018. Ethical Tensions from New Technology: The Case
of Agricultural Biotechnology (ed. H.S. James, Jr.)

83

84

D.M. Strauss

the very existence of the Terminator serves
as a reminder that there is virtually no limit
as to what might be developed in the future
through this novel technology.
In the USA, GM crops now comprise almost all of the plantings and the vast majority of component products in the US market
(Strauss, 2012a). Recent statistics indicate
that GM crops accounted for 94% of soybeans, 92% of corn and 96% of cotton planted in 2017; and GM canola, squash, papaya,
alfalfa and sugar beet were widely planted
(USDA, 2017a). The Grocery Manufacturers Association (GMA) reported in 2005
that 75% of all processed foods in the USA
contained a GM ingredient, including almost every product with a corn or soy
ingredient and some with canola or cottonseed oil; this figure has continued to be
widely cited. However, projecting from the
exponentially higher plantings since then,
the prevalence should be substantially
higher today. The current GMA position
statement emphasizes the proliferation of
GMOs:
It is important for our consumers to know
that this technology is not new. In fact, it
has been around for the past 20 years, and
today, 70–80% of the foods we eat in the
United States, both at home and away
from home, contain ingredients that have
been genetically modified. If the ingredient
label on any food or beverage product
contains corn or soy, they most likely
contain genetically modified ingredients,
as a very high percentage of those crops
grown in the U.S. use GM technology. In
addition, a high percentage of other
ingredients in the U.S., such as sugar
beets, are grown with the use of GM
technology as well. (2017, n.p.)

Yet the widespread use of GMOs is unknown to most consumers because, unlike the
European Union and the broader international community where more than 60 countries
require labeling, the USA does not dictate
mandatory labeling, rigorous approval or
monitoring of GM plants and foods (Strauss,
2006; Consumer Reports, 2014). Moreover,
due to the absence of long-term studies, the
level of safety and the effect on human health
and the environment remain uncertain.

Surveys on GM foods reveal that a significant majority of consumers believe that the
government should include ethical and moral
considerations when making regulatory decisions about genetic engineering. Moreover,
consumers seek an active role from regulators to ensure that new products are safe
(Strauss, 2007). Consumer polls uniformly
demonstrate that a vast majority of US citizens would like GMOs to be labeled (Center
for Food Safety, 2017). For instance, a recent
Consumer Reports National Research Center
survey found that 92% of Americans prefer
GM foods to be labeled and more than 70%
indicated that they do not want GMOs in
their food (Consumer Reports, 2014). This is
a critical area where examining the ethical
implications can lead to further developments
in the law as a means for the community to
address and resolve these issues.
The juxtaposition between the proliferation of agricultural biotechnology and consumer concerns will be explored in view of
the critical role of food safety in human
health and the environment. To this end, the
next section examines the key ethical issues
arising from genetic engineering, particularly
the right to informed consent and conflicts
of interest in studies and scientific research
that may hamper inquiry into the possible
long-term risks. The chapter then analyzes
the new federal statute recently passed in
the USA purportedly to label these foods
and evaluates whether in fact it does so in an
effective and meaningful way to fulfill these
consumers’ rights. The chapter highlights an
approach that takes into account these ethical tensions and shifts the dialogue from
public outcry to the policy and regulation
arena. Accordingly, this proposal embraces
participation of all stakeholders, education
of the public on the potential risks, development of comprehensive labeling to enable
informed consumer choice and establishment
of a more active and independent role for
government agencies in regulating biotechnology companies. The chapter concludes by
providing queries to assist policy makers in
implementing a new regulatory framework
in the USA, recognizing that consideration
be given to ethical tensions in shaping the
international policy arena.

Genetically Modified Organisms in Food: Ethical Tensions and the Labeling Initiative

Ethical Tensions in Connection
with GMOs
To recognize an ethical perspective in the
ongoing discussions about GMOs, the Food
and Agriculture Organization of the United
Nations (FAO) formed an expert panel on
ethics in food and agriculture, which met in
four sessions and issued reports on specific
focus areas (FAO, 2007a). The first report of
the FAO panel, ‘Ethical issues in food and
agriculture’, introduced ethical questions
related to its mandate, such as: What is the
value of food? What is the value of human
health? What is the value of nature and natural resources? The FAO panel recognized as
principles the right to adequate food, optimization, trust, equity and informed consent
in identifying these ethical concerns as central
to the debate about the future (FAO, 2001a).
The FAO’s second report, ‘Genetically
modified organisms, consumers, food safety and the environment’, stressed the role
of ethical considerations in food and agriculture with regard to GMOs as well as food
safety and the environment (FAO, 2001b).
Issues examined included ownership of the
necessary tools to produce GMOs, potential
consequences of their use and undesirable
effects that could result from their application, both now and in the future. Most
important, the report advocated the participation of all stakeholders in making decisions regarding GMOs, emphasizing that
‘[w]idely communicated, accurate and objective assessments of the benefits and risks
associated with the use of genetic technologies should involve all stakeholders . . .
Experts have the ethical obligation to be
proactive and to communicate in terms
that can be understood by the lay person’
(2001b, p. 25).
The FAO’s third report delved further into
the risks of GMOs and the ethical imperative
to make human health and the environment
the paramount concern and accordingly restrict the use of this technology:
Genetic engineering introduces a new
uncertainty, as it affects the genetic design of
plants and animals and thus the composition
of our food. The Panel reiterated the concern
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expressed in its earlier sessions over the
potential environmental, health and
socio-economic impacts of genetic
engineering and genetically modified
organisms (GMOs). Unless there is an
overriding advantage that is apparent, the
Precautionary Principle, which is the
foundation of the Cartagena Protocol on
Biosafety, would point to a preference for
non-genetically engineered food. Even when
there is an obvious advantage, an exhaustive
testing of the safety of the genetically
engineered food is required. (2005, p. 4)

In its fourth and final report, the FAO
continued to emphasize
the ethical requirement to avoid the
risks of, while sharing the benefits of,
biotechnologies as part of the advancement
of science, which also involves an
examination of the ethical issues related to
intellectual property rights . . . Ethical
considerations of decision-making in relation
to genetically modified organisms from the
perspective of the consumer, food safety and
the environment are closely related to this
issue. (2007b, p. 10)

Thus, a discussion of ethical tensions is warranted in the public arena, and all of the
stakeholders should have a voice in determining the policy decisions that consequently ensue.
These considerations have induced the
European Union and other countries in accordance with the precautionary principle to
limit the use of bioengineered foods and require labeling of foods with GM ingredients.
The continued development of genetically
modified plants raises several moral principles, such as respect for nature and the value
of life; consideration of the environment;
and equity, power and the economically disadvantaged (Strauss, 2007). The most significant ethical tensions will be explored further
below: the right to informed consent and
the latent impact of conflicts of interest in
scientific research.
The right to informed consent

The foregoing reluctance of the US government to establish a rigorous labeling scheme
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for the treatment of GM crops and GMOs in
food raises critical ethical tensions. For
consumers, the lack of clear and meaningful
disclosure of the fact that their food was
developed using bioengineering techniques
violates the right of informed consent. From
an ethical perspective, particularly a Kantian
model, US citizens have been deprived of their
autonomy and freedom of choice (Strauss,
2007). Individuals have the fundamental
right to know what they are buying and eating before making a purchasing decision.
An economic model also supports transparency and disclosure of this information
(Brussel, 2003). According to this reasoning,
‘the market for GMOs at both the consumer
and producer level is unable to achieve a rational, efficient and socially optimal result
due to asymmetrical information’ (p. 430).
Without adequate information, consumers
cannot make rational decisions about
whether to purchase and consume GMOs,
farmers do not have the tools to negotiate
with biotech seed producers and organic
farmers cannot effectively allocate resources
to protect their crops from contamination
by genetic drift. This market can only function efficiently
if a mechanism is established for ensuring that
rational, scientifically-based information on
the effects of GMOs on human health,
agricultural production, and the environment
is available to the public. Because transaction
costs would be prohibitively high for
individual consumers or farmers to obtain
such information, a system of mandatory
disclosures tied to discretionary participation
in the market for GMOs should be established
by the government. (Brussel, p. 432)

The government has a responsibility to
protect its citizens, particularly in such a critical area as the safety of the food supply. As a
matter of ethics, the as yet unknown risks
must not be placed on the unsuspecting public rather than on the companies who have
created these genetic modifications. To do so
would betray consumers’ trust in their government to ensure their health and well-being
as fiduciaries acting on their behalf. The Food
and Drug Administration (FDA) has recognized this mandate in its regulatory approach
to other areas of the food supply, for example,

applying a zero-risk policy to prohibit the introduction into the food supply of food and
color additives determined to cause cancer in
laboratory animals (Strauss, 1987).
Moreover, in an area where the FDA perceives there to be no safety risk – food treated
with ionizing radiation – it has nonetheless
required mandatory labeling of such foods,
with the international (Radura) symbol for
radiation along with the statement ‘Treated
with radiation’ or ‘Treated by irradiation’ on
the food label (FDA, 2016). In mandating a
disclosure on all irradiated foods, the FDA
was cognizant of widespread consumer concerns about food irradiation. According to
the agency, ‘the large number of consumer
comments requesting retail labeling attest
to the significance placed on such information by consumers’ (Strauss, 2006, p. 184;
United States, 2012). Yet the FDA has not
applied this reasoning for GMOs in food,
where only nonbinding recommendations
for voluntary labeling have been its policy
(FDA, 2015).
Consumers have the right to choose what
they eat, and informed choice can only be
realized through mandatory labeling on the
package that is accessible and understandable. According to Consumers International,
consumers’ desires and opinions should be
respected due to a fundamental right to know
and make informed decisions (Halloran and
Hansen, 1999). For example, a lack of labeling as to the presence of an introduced gene
removes the individual’s right to avoid
known allergens and control their own fate.
Eight percent of children in the USA have
food allergies, some of which can be fatal
(Kolehmainen, 2001). When Pioneer HiBred spliced Brazil nut genes into a soybean
to improve its protein content, the altered
soybean provoked severe allergic attacks in
eight individuals sensitive to Brazil nuts but
not soybeans (Nordlee et al., 1996). Without
a label alerting consumers that a soybean
could contain genes from a highly allergic
nut, even individuals aware of their severe
allergies would have no warning. As a matter
of policy, vital information about the transgenic processing must be made available to
those individuals who could be affected by
important health risks (Nestle, 1996).
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While the potential risks generate a need
for labeling of the presence of GMOs, such
an approach is also required beyond safety
issues, as a matter of taste and preference
and for many health-related reasons. It must
be recognized that many consumers make
food choices based on religious, ethical and
environmental considerations, for example,
deciding not to eat veal, mass-produced
chickens or non-organic produce. If biotechnology raises similar ethical, health and environmental concerns, it is not irrational for
people to act on these preferences and aversions to risk (Teitel and Wilson, 1999). In
order to make these informed decisions,
food products must be effectively labeled. As
a matter of ethics and public policy, ‘[s]ince
labeling laws are created to meet consumer
needs, consumer opinion should be respected’ (Halloran and Hansen, 1999, n.p.).
The decision to allow the public to consume
unlabeled genetically engineered (GE) food
strikes some people as ‘grossly undemocratic
and slanted too far in favor of corporate interests’. ‘Should our society allow the purported
commercial rights of a corporation to supersede the citizen’s right to make informed
decisions in the marketplace?’ (Teitel and
Wilson, p. 61). ‘Every person has a right to
make choices about what they eat. Every person has a right to know’ (Strauss, 2007, p. 28).
With an increasing crescendo of proponents,
this concept has been building momentum as a
‘Consumer Right to Know’ policy grounded on
a number of concerns apart from health and
safety, including religious, ethical, dietary restrictions and environmental objections
(Keane, 2006; Nauheim, 2009; Begley, 2017).
A recent study by the National Academies
of Sciences (NAS, 2016) provided support for
labeling of GMOs, not based on safety concerns
but expressly on the ethical grounds of the consumers’ right to know policies that respect consumer autonomy and fairness, reasoning that:
‘if non-GE labeling is voluntary, many products
would have no label information about GE
content. Consumers would not know whether
the product contained GE ingredients and
so would be deprived of the ability to make an
informed choice about each product’ (2016,
pp. 305–306). In its most significant statement, the NAS committee concluded:
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Mandatory labeling provides the opportunity
for consumers to make their own personal
risk-benefit decisions (regardless of the
regulatory determination of safety) and to
express a preference for a method of
production. A voluntary non-GE label places
the burden on consumers who want to avoid
GE foods to search for non-GE products and
provides no information to consumers who
may not be actively searching for the
information but who might be informed by
the label. Voluntary labeling also may not
help consumers who cannot afford the kinds
of foods that will be voluntarily labeled.
(2016, p. 306)

For consumers who are careful about the
content of the food they eat, choosing organic foods may be an option, but it is not an
equitable and practical solution for the majority of Americans. Organic foods tend to
be more expensive than non-organic products and they are not available for all types
of food, stores and areas of the country.
Thus, most consumers do not have the genuine choice and access to purchase organic
foods as an alternative to what has previously been known as ‘traditional’ foods (Strauss,
2007). Moreover, issues of cross-contamination increasingly threaten the integrity and
economic viability of the organic food supply (WHO, 2005).
The government has the ethical obligation to protect the safety of the mainstream
food supply for all of its citizens. The FAO
expert panel on ethics recognized that:
[t]he right to adequate food, as understood
today, carries with it obligations on the part
of states to protect individuals' autonomy
and capacity to participate in public decisionmaking fora, especially when other
participants are more powerful, assertive or
aggressive. These obligations can include the
provision of public resources to ensure that
those fora take place in a spirit of fairness
and justice. (2001b, p. 25)

The FAO second report concluded that
this right has not been fulfilled in connection with genetically engineered products.
The most important stakeholders have been
excluded from the process because:
[c]itizens have a direct interest in
technological developments, yet there are
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obstacles to their participation in
decision-making that must be acknowledged
and overcome. The public has not been
adequately informed about the application of
gene technology to food production or the
consequent potential impacts on consumers’
health and the environment. (2001b, p. 25)

As a result, with the confusing and conflicting jumble of claims in the media, ‘the public
is losing faith in scientists and government’
(p. 25).
Following similar reasoning, Geoffrey
Podger, as Executive Director of the European Food Safety Authority (EFSA), promoted
a labeling approach as a means to regain the
support of the public. He explained that the
European opposition to GMOs was based on
ethical grounds as a reaction to being denied
a choice when GMO and non-GMO varieties
could not be differentiated. Thus, the European
regulatory approach arose in part as a solution to this ethical and practical duty to inform.
The advantage of labeling is that it provides
a choice ‘[a]nd while the people who insist on
choice may be quite a small part of the population, they are very vociferous and they are
often in positions of power and prominence’
(Podger, 2004, n.p.). Accordingly, the key to
public perceptions is a transparent regulatory process that gives people readily available
information on the science.
The responsibility of government to protect its citizens and respond to their concerns should necessitate, at the very least,
mandatory labeling and monitoring of
GMOs in food. Past studies have found that,
unlike the Europeans, American consumers
have generally trusted their government
and regulatory agencies. Attitudes toward
the government link closely with public perceptions of biotechnology, press coverage
and policy formation (Gaskell et al., 1999).
This fact offers an even greater reason why it
is critical that the government does not betray that trust in an area as fundamental
and critical as food safety.
Most recently in the USA, public outrage at
being denied a choice has generated a grassroots political effort to raise consciousness
of consumers and alert them as to what they
are not being told, while advocating labeling
(Justlabelit, no date). At the local, state and

even federal levels, legislative efforts have
attempted to respond to the public’s right to
know, as well as the safety concerns for consumers and farmers. But a review, below, of
the history and current status of those initiatives reveals that these noble goals have
not yet been satisfactorily achieved.

Conflicts of interest in studies
and scientific research

Several sources have raised the issue of the
close connection between the academic community involved in research and the industries or patents they seek to develop (Hoffman
and Sung, 2005). This direct financial stake,
via stock options or patent participation,
creates an inherent conflict of interest. One
fear is that ‘the lure of profit could color scientific integrity, promoting researchers to
withhold information about potentially dangerous side-effects’ (Batalion, 2009, n.p.).
As a result of this conflict of interest and disincentives for long-term studies, the actual
risks of this novel technology remain largely
unknown.
Well-funded programs in plant genetics
and genetic engineering are supplanting
research to enhance organic methods and
other low-input alternatives. A 1990 study
discovered that ‘from [ten percent] up to
one third of biomedical researchers at prestigious universities such as Stanford and
MIT had direct corporate ties’ (Tokar, 1999,
n.p.). With the exponential growth of the
biotechnology industry since then, today’s
figures are no doubt even higher. These ties
continue to shift more public funds into projects that support the research agenda of the
biotechnology industry.
Some groups have also expressed concern that intellectual property incentives
limit the development of more beneficial
genetically engineered crops. In July 2003,
a coalition of public-sector research institutions announced the formation of the Public-
Sector Intellectual Property Resource for
Agriculture (PIPRA) (Atkinson et al., 2003;
PIPRA, no date). Funded by the Rockefeller
and McKnight Foundations, PIPRA contends
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that ‘the benefits of much publicly funded
research come to private industry through
university technology transfer programs,
limiting universities’ flexibility to conduct
research’ (Hoffman and Sung, 2005, p. 15).
As a result, biotechnology patents may
not be utilized for developments with
little commercial value that would help the
poor and promote the original goal of food
security.
Because the research at public institutions is often heavily influenced by the source
of funding, this predominantly private backing has diverted research time and money
away from projects that would benefit ‘the
public good, such as biological control, organic production systems and general agroecological techniques’ (Altieri and Rosset, 1999,
n.p.). This situation has sparked suggestions
that ‘[c]ivil society must request more research on alternatives to biotechnology by
universities and other public organizations’
(1999, n.p.).
Moreover, one of the significant problems associated with the privatization of
biotechnology rights is the company’s restriction of information.
While the basic realities of modern business
clearly underscore the need for
confidentiality, it is also true that
confidentiality provisions are often used as a
means of avoiding disclosures. In the face of
increasing recognition that activities,
including especially species introduction, in
one country may have serious impacts on
neighbouring countries, labelling and other
access to information is increasingly
addressed at international and regional
levels. (Prakash et al., 2011, p. 7)

Sharing of some of this information is crucial
for risk assessment, long-term studies and
developing buffer zones between genetically
engineered and conventional or organic
crops that would avoid spreading these risks
exponentially through cross-contamination.
In its recent report, the NAS acknowledged that any new food ‘may have some
subtle favorable or adverse health effects
that are not detected even with careful
scrutiny and that health effects can develop
over time’ (2016, p. 19). It recommended
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additional public funding for research,
particularly in cases where early published
studies produce ‘equivocal results’ regarding health effects of a GE crop, ‘using trusted
research protocols, personnel, and publication outlets to decrease uncertainty and
increase the legitimacy of regulatory decisions’ (p. 19).
According to one examination of the risks
and precautions arising from GMOs:
Regulation of GMO deals with a
transscientific problem, that is, the
resolution of the problems is beyond the
competence of the scientific system. Public
perception and acceptance are dependent on
trust and whether the products or processes
benefit them as citizens and consumers. To
take proper accounts of uncertainties and
public concern would help to capture the
benefits, minimize the risk, and provide goals
for future development and use of genetic
engineering. (Prakash et al., 2011, p. 11)

Critical to maintaining the public trust will
be embracing transparency and disclosure
through a comprehensive and effective labeling policy.

The New DARK Act and Preemption
of State Initiatives
In the shadow of these ethical tensions
emerged a new piece of federal legislation
that extinguished grassroots efforts to require mandatory labeling of GMOs in the
USA. Attempts to regulate the safety and
labeling of GMOs had been raised unsuccessfully every year at the federal level through
bills introduced in Congress that died a quiet
death in committees. For example, in May
2002, H.R. 4814 was one of five bills introduced by Representative Dennis Kucinich
(Democrat-Ohio) that sought to expand the
regulation of agricultural biotechnology. On
2 May 2006, Representative Kucinich introduced the ‘Genetically Engineered Food
Safety Act’ (H.R. 5268, 109th Congress
2006) and four other bills regarding GMOs
(Strauss, 2007). Representative Kucinich introduced similar bills in the 111th Congress,
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including legislation that would have protected farmers and shifted liability to the
biotech companies (H.R. 5577, 111th Congress 2010) (Strauss, 2012b). One of the
most recent efforts, introduced into the US
Senate on 2 March 2016 by Democratic
Senators Jeff Merkley, Patrick Leahy, Jon
Testor and Dianne Feinstein, the ‘Biotechnology Food Labeling Uniformity Act’
(S. 2621, 114th Congress 2015), would have
informed consumers of the presence of GM
ingredients in their food while giving several
options to food manufacturers for how to
indicate this information on the Nutrition
Fact Panel (Merkley, 2016). But this proposed legislation was superseded by the one
federal bill that did ultimately become law,
discussed below.
At the state level, momentum for labeling
appeared to build with the passage of several
statewide labeling initiatives, which many
hoped would take hold and lead to a stringent
mandatory labeling under federal law that
would follow the states. In 2013, Connecticut
became the first state to pass legislation for
labeling GMOs in foods, requiring that the retail packaging contain the clear and conspicuous words ‘Produced with Genetic Engineering’ and redefining the FDA’s use of the term
‘natural food’ to include food that has not
been genetically engineered. However, the
Connecticut statute provided that the law
would not take effect until the passage of similar legislation by four additional Northeast
states, with a total aggregate population of
more than 20 million, one of which borders
Connecticut (Connecticut General Statutes,
2013). Soon after, Maine passed a similar law
requiring genetically engineered food and
seed stock to be conspicuously labeled as
‘Produced with Genetic Engineering’ and
prohibiting such foods from being labeled as
‘natural’. But the Maine statute also contained
a ‘trigger’ clause providing that at least five
contiguous states must pass comparable laws
(Maine Legislature, 2013). Numerous other
states had launched their own labeling bills,
some of which were defeated (e.g. California)
but were slated to be reintroduced by advocates (Center for Food Safety, no date).
The most successful and definitive of these
state laws was passed in Vermont (Vermont

General Assembly, 2014) in May 2014, with
an accompanying rule, ‘Consumer Protection Rule 121’, which like the previous states
required that food entirely or partially produced with genetic engineering be labeled as
such. The law applied to raw agricultural products such as corn and squash as well as processed foods like crackers, soda and cereals.
Its comprehensive scheme applied to producers, processors, distributors and retailers.
Exemptions included processed foods that
would otherwise have been subject to the labeling requirement due to containing one or
more materials that have been produced
with genetic engineering, in which the genetically engineered materials in the aggregate do not account for more than 0.9% of
the total weight of the processed food.
The Vermont law was set to go into effect on
1 July 2016, when the biotechnology industry intervened and succeeded in pushing
Congress to cut short the state initiatives.
The National Bioengineered Food Disclosure Standard (United States, 2016), pejoratively called the DARK (‘Denying Americans
the Right to Know’) Act like a previous version that had been defeated, was signed into
law by President Obama on 29 July 2016. It
amended the Agricultural Marketing Act of
1946 to require the Secretary of Agriculture
to ‘establish a national mandatory bioengineered food disclosure standard with respect
to any bioengineered food and any food that
may be bioengineered’ (Section 293). In a
blow to community activists and consumer
groups, this statute pre-empted the states
from passing their own – and Vermont from
implementing its enacted – GMO labeling
laws. Furthermore, the USDA sent preemption letters to the governor of every state
(USDA, no date(a)). If challenged in court,
however, this may be held to be an improper
use of preemption, as the federal law currently does not present the requisite characteristics of a comprehensive regulatory
scheme. While technically a law requiring
labeling, it appears on its face to be so minimal and likely ineffective in its conveyance
of information to the consumer that it may
be determined to lack adequate and meaningful labeling and thus violate the right of
informed consent and effective choice.
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With respect to food, the federal statute
defines the term ‘bioengineering’ as a food
‘that contains genetic material that has been
modified through in vitro recombinant deoxyribonucleic acid (DNA) techniques . . . for
which the modification could not otherwise
be obtained through conventional breeding
or found in nature’ and limits its scope to
foods that are already subject to labeling requirements under the Federal Food, Drug,
and Cosmetic Act, the Federal Meat Inspection Act, the Poultry Products Inspection Act
and the Egg Products Inspection Act, as well
as the predominance of its ingredients (Sections 291 and 292). Although labeling for
these substances in food will be mandatory,
it gives manufacturers a choice of the disclosure on the package via ‘text, symbol, or
electronic or digital link’ (e.g. QR code accessed with a smartphone) (Section 293(b)
(2)(D)). Small food manufacturers can choose
to comply instead by placing a telephone
number accompanied by appropriate language to indicate that the phone number
provides access to additional information
and an internet website with disclosure of
bioengineering ingredients; the telephone
number disclosure must only state, ‘Call for
more food information’ (Sections 293(b)(2)
(F)(ii) and 293(d)(1)(B)).
Critics of this new law note that it does
not specifically mandate that manufacturers
have to post a label or warning that the food
contains GMOs. Consumer groups have expressed concern that manufacturers will
choose the method that gives the least
amount of information or makes it difficult
for consumers to ascertain this information
in a timely and effective way in order to be
able to make a choice before their purchasing decision (Nat, 2016; Begley, 2017). This
problem will be exacerbated by technological
limitations if the consumer does not have
cell service, a phone capable of reading a QR
code, or the comfort level and knowledge to
do so (Justlabelit, no date; Center for Food
Safety, 2017). A national survey confirmed
that 88% of American voters prefer GMO labeling printed on the package over bar codes
that would be scanned by a smartphone app
(Melman Group, 2015). In addition, consumer advocates object to the narrow definition
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of ‘bioengineered’ and scope of the labeling
advocated by the industry, urging instead
that ‘all foods produced through genetic
engineering are labeled; including those
derived from genetically engineered sources, such as highly refined sugars and oils
and processed corn and soy ingredients’
(McCann, 2017, n.p.). Moreover, any threshold set by the USDA should be consistent
with international standards – the mandatory disclosure of 0.9% by individual GE ingredient (2017, n.p.).
Unlike previous statutes that put food
labeling in the purview of the FDA, the
law designated the Agricultural Marketing
Service (AMS) of the USDA as the agency
responsible for promulgating additional regulation that would fill in the details to establish
a ‘national mandatory system for disclosing
the presence of bioengineered material’
(USDA, no date(a)). The USDA has formed a
working group to develop a timeline for rulemaking and posted questions on its website
in the summer of 2017 to seek input on a
series of issues left open by the legislation to
aid in its drafting of the rules. These questions include the scope, threshold levels and
definitions of a ‘bioengineered food’; the
type of text, symbol or digital/electronic
link that should be designated ‘if a manufacturer chooses to use’ it; alternatives for ‘very
small or small packages’; and definitions for
the stated exclusions, such as ‘small’ and
‘very small manufacturers’, ‘restaurants and
similar retail food establishments’ (USDA,
no date(b)). AMS received over 112,000 responses from individuals and organizations
to be used in its drafting of the proposed
rule, issued with an additional public comment period.
The USDA also commissioned a study ‘to
identify potential technological challenges
that may impact whether consumers would
have access to the bioengineering disclosure
through electronic or digital disclosure methods’ and published the results on 7 September 2017 (USDA, 2017b). Among its most
significant findings was the fact that 85% of
consumers experienced technical challenges
when using mobile apps for scanning digital
links: ‘In addition, most apps contain advertisements that confuse consumers and run
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counter to how the Law requires disclosure
when regulations are finalized and implemented’ (2017b, p. 4). Pursuant to the law,
the USDA is required to have the final rules
in place by 29 July 2018, two years after the
passage of the legislation.
In view of prospective future court challenges, it would be prudent for the USDA to
take the opportunity to strengthen labeling
requirements to a level akin to Vermont and
other state initiatives or international standards. The Vermont Attorney General’s Office
has already announced its intention to ‘take
an active role as the labeling fight shifts
from the legislative process in Congress to
the regulatory process at the USDA . . . We
will work hard to give consumers the same
access to information, in plain English, that
they had under Vermont’s law’ (2016, n.p.).
Pressure will be wielded by consumers, antiGMO groups and other stakeholders to determine if this will be only the first step in a
comprehensive and effective mandatory
federal labeling scheme or a temporary defeat for states that will ultimately prevail
over federal obstructionism. One way or another, the US government must respond to
the increasing crescendo of the public outcry
for transparency and disclosure in the debate
over food safety. Hopefully these governmental agencies will be guided by their charge and
uphold their duty to the public to take into
account consumer concerns regarding labeling
and to make paramount the safety of the food
supply for the average American consumer.

A Framework that Addresses these
Ethical Tensions
In light of ethical concerns and individuals’
comfort levels in assessing whether the risks
are acceptable, American consumers should not
be bound to accept the possible consequences
of GM foods without their knowledge and
consent. With scientific uncertainty about
the risks of consuming GM foods unlikely to
be resolved in the near future, ethical concerns should be the paramount factor in determining a model of labeling, segregating
and monitoring for GM foods.

Reflecting on the ethical tensions that biotechnology creates prompts one to consider questions that should be raised and
utilized to construct a more appropriate
regulatory response. The current regulatory
framework is inadequate because it predates
the advent of this technology and forces regulators to conform substances created
through a novel process into preexisting and
longstanding notions of safety and efficacy.
Better public policy would result from
approaching this area from an alternative
perspective. Under what conditions do consumers have a right to know the process by
which their food has been produced? The US
already requires labeling to inform consumers about some food production cases (e.g.
irradiation). Given the uniqueness of biotechnology and its potential for harm,
should this change the way we think about
the right to know and implore us to answer
this question in the affirmative?
The way of approaching market approvals
and labeling requirements in the past has
been to focus only on the composition and
safety of the product itself without considering the potential risk inherent in the technology. Biotechnology is so fundamentally
different that it forces us to rethink that approach. Biotechnology raises issues separate
from whether to label the product as to the
presence of a particular ingredient or lack
thereof, which has been the traditional approach of the FDA. Genetic engineering of
food also goes beyond the existing criteria
for labeling of the potential for harm embodied by the concept of ‘substantial equivalence’, regardless of whether the product
itself is or is not different. Under the current
FDA policy, if a genetically engineered product does not appear to be substantially different than its conventional counterpart, no
special labeling or animal testing is required.
‘From FDA’s perspective, biotechnologically-
produced products are seen as substantially
equivalent to conventional food products
because, in the agency’s view, there is no scientific basis to presuppose that biotech
foods are more risky or substantially different from other food products’ (Strauss, 2006,
p. 183). However, there is no definition
provided in the regulations for substantial
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equivalence or clear guidelines stipulating
what to examine and how similar the items
in question should be; this concept has been
discredited in Europe as unscientific and not
adequate to justify a lack of safety assessments (Strauss, 2006). Biotechnology is so
extraordinary that there are many unknowns
and scientific uncertainty, with potential
risks inherent in the technology itself.
This innovation calls for a new way of thinking because it would be inappropriate for
regulators to impose an existing framework
on it. Policy makers should recognize this
matter as unique due to the unknowns and
possible risks.
The issue of risk is made even more compelling due to the fact that science has not
yet advanced to measure and assess these
risks using standard risk assessment techniques. Thus policy makers cannot turn to
science alone to provide the answers to the
pressing questions. A more precautious policy could create the proper incentives for the
development of more advanced risk assessment procedures, as well as improved detection methods and long-term studies of safety.
Moreover, a more prudent policy with greater emphasis on public safety concerns would
be consistent with the government’s recent
proactive approach towards food safety embodied in the Food Safety Modernization
Act (Strauss, 2011). Until such time as these
risks can be ascertained with a higher degree
of certainty, consumers of these products
should be given a choice and allowed to
weigh their own personal comfort levels in
their purchase and consumption decisions.
In view of this scientific uncertainty, effective labeling should be an important component of the revised regulatory framework,
along with an education campaign as to the
meaning and significance of these GE designations.
This discussion relates to a more fundamental question: when a new technology is
introduced, when do people have the right
to be informed and what do they have a right
to be informed about (e.g. that the product
was made through this method)? This concern goes beyond a focus on the potential for
harm. As the Terminator gene illustrates,
there is no limit to what might be developed
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through genetic engineering because biotechnology is so profoundly different from
traditional crop and animal breeding practices. As a consequence, society needs to develop a different way of looking at it – at the
very least labeling and educating the public –
and ultimately introducing a new regulatory
scheme so that as the science and technology develops, new inventions will be incorporated into that scheme. For example,
requiring better detection methods and risk
assessment for the approval process would
both provide incentives to develop that new
technology and guide the future direction of
the science.
A consideration of these issues highlights
the fact that ethical principles must shape the
solution for the treatment of biotechnology
food products. The incorporation of ethics
into policy development should involve all
stakeholders: farmers, consumers, the environment, underprivileged populations and
the agricultural biotechnology industry.
Recognition of the inherent conflicts of interest also necessitates a more active and
independent role of regulatory agencies in
relation to the biotechnology companies. An
important part of this framework would be
clear and comprehensive labeling, which is
essential for informed consumer choice, as
well as a sharing of information and education on the science, including all potential
and discovered risks to human health and
the environment.
A group of scientific experts identified
three important components for risk management: impact assessment, public awareness/
participation and the design of regulatory
systems. Above all is involvement of the
public: ‘It is not possible to overstate the
importance of the public’s contribution to
effective decision making, as well as the importance of public awareness, within the
context of government decisions on matters
and activities affecting the environment’
(Prakash et al., 2011, p. 6). Under this analysis, disclosure and transparency should extend beyond public access to governmental
documents and processes:
[T]here are other mechanisms by which
public awareness and access to information
can be encouraged, including product
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labeling, food safety standards, and general
consumer protection laws, all of which are
designed to foster awareness and communicate
public preferences to the commercial
proponents of GMOs in a way that will get
their attention. (2011, p. 6)

In order to be effective, such labeling must
be ‘accurate, specific, and clearly expressed
in understandable language, unbiased, and
based on full disclosure of the relevant facts
by the GMO proponents’ (Prakash et al.,
2011, p. 6).
The WHO study also recognized the need
and responsibility for communicating risks
to the public so that ‘ethical components of
food-safety decisions are clearly identified
as early in the process as possible’ and ‘value-laden choices made by risk managers are
made in an open, participatory process that
respects the rights and roles of all stakeholders’ (2005, p. 56).

Conclusion
In view of the most recent federal labeling
statute in this area, the predominant query
to consider may be the following: Do the current regulations, or lack of adequate and
meaningful labeling, violate our responsibilities to others by not allowing them a choice
as to whether they knowingly and willingly
assume the risks of ingesting these genetically engineered substances? Efforts to quell
the public outcry by preempting state and
local community labeling initiatives would
be better directed to incorporating these desires into the international policy arena.
The ethical implications are clear, followed
by the expectation that the legal system
should fill in the ethical gap as it has done in
so many other areas and, at the very least,
require meaningful labeling, pre-market
approval and monitoring of GMOs in food
products and ingredients. Fully informing
the public and transparency in the regulatory
process are the keys. Incorporating ethical
tensions in the policy and regulation arena
requires US policy makers to respond appropriately to the consumer demands that led
to grassroots efforts and embrace rather

than suppress these initiatives. Mandatory labeling that clearly and effectively discloses genetically engineered ingredients
and processes would be the responsible
next step.
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